Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Levi-Garraway"

80 News Found

Roche’s Lunsumio VELO–Polivy combo moves closer to FDA decision after strong lymphoma trial results
News | June 23, 2026

Roche’s Lunsumio VELO–Polivy combo moves closer to FDA decision after strong lymphoma trial results

The safety profile of the Lunsumio and Polivy combination was consistent with the known profiles of the individual study medicines


FDA fast-tracks Roche cancer drug filing after landmark trial shows 50% recurrence reduction
Drug Approval | June 23, 2026

FDA fast-tracks Roche cancer drug filing after landmark trial shows 50% recurrence reduction

The FDA has granted Priority Review, setting a target decision date of 9 October 2026, potentially accelerating access to a new treatment option for a subset of patients with high-risk colon cancer characterized


Roche signs up to $2.3 billion deal with Nurix for BTK degrader Bexobrutideg
News | June 08, 2026

Roche signs up to $2.3 billion deal with Nurix for BTK degrader Bexobrutideg

The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases


FDA fast-tracks Roche’s giredestrant review as data signal potential shift in early breast cancer care
Drug Approval | June 03, 2026

FDA fast-tracks Roche’s giredestrant review as data signal potential shift in early breast cancer care

The filing is backed by Phase III data from the lidERA Breast Cancer study


Roche’s MS drug fenebrutinib delivers striking Phase III results by cutting relapse rates by 58%
Clinical Trials | April 22, 2026

Roche’s MS drug fenebrutinib delivers striking Phase III results by cutting relapse rates by 58%

The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints


ENSPRYNG cuts MOGAD relapse risk by 68% in landmark Phase III trial: Roche
Clinical Trials | April 22, 2026

ENSPRYNG cuts MOGAD relapse risk by 68% in landmark Phase III trial: Roche

The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents


Roche reports Phase III persevERA breast cancer trial results
Clinical Trials | March 11, 2026

Roche reports Phase III persevERA breast cancer trial results

Giredestrant shows promise despite missing primary goal


Roche’s Gazyva shows breakthrough results in Lupus phase III trial
Clinical Trials | March 07, 2026

Roche’s Gazyva shows breakthrough results in Lupus phase III trial

Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints


Roche’s experimental obesity drug shows strong weight-loss results in mid-stage trial
News | March 07, 2026

Roche’s experimental obesity drug shows strong weight-loss results in mid-stage trial

The company announced positive topline data from the Phase II ZUPREME-1 trial


Roche’s Fenebrutinib moves closer to being first BTK inhibitor for relapsing and progressive MS
Clinical Trials | March 02, 2026

Roche’s Fenebrutinib moves closer to being first BTK inhibitor for relapsing and progressive MS

Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology